Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Aim: To assess the safety and efficacy of omecamtiv mecarbil compared with placebo in heart failure (HF) patients.
Methods: We searched PubMed, Web of Science, Cochrane Library, and SCOPUS until August 15th, 2021. We included all randomized controlled studies comparing omecamtiv mecarbil with placebo in heart failure patients. The meta-analysis was carried out using Rev Man software V5.4.
Results: A total of eight studies were included in our systematic review. Pooled analysis showed that omecamtiv mecarbil is not associated with increased incidence of death, any adverse events, hypotension, heart failure, ventricular tachyarrhythmia, dyspnea, dizziness, and serious adverse events. Regarding the efficacy, omecamtiv mecarbil significantly reduced heart rate with some studies demonstrating its significant improvement in left ventricular ejection fraction and systolic function.
Conclusion: Omecamtiv mecarbil is a well-tolerated drug in heart failure patients. The limited data regarding the efficacy suggested that it may improve ejection fraction and systolic function.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9243594 | PMC |
| http://dx.doi.org/10.1016/j.ihj.2022.03.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Breaking new ground in heart failure management: novel therapies and future frontiers.
Front Cardiovasc Med
August 2025
Department of Internal Medicine, Kirk Kerkorian School of Medicine at the University of Nevada, Las Vegas, NV, United States.
Heart failure (HF) management is advancing in the field of cardiology, driven by the increasing availability of progressive medications. Emerging pharmacological therapies in heart failure management include SGLT-2 inhibitors, ARNI, Vericiguat, and Omecamtiv. Other novel therapies that are changing the scope of HF management include IV Iron therapy and new antifibrotic agents, such as pirfenidone and pamrevlumab.
View Article and Find Full Text PDFSerum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial.
Eur Heart J
August 2025
British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Background And Aims: The frequency and prognostic significance of abnormalities in serum magnesium concentrations have not been described in a contemporary HF population. The authors evaluated the prognostic significance of magnesium concentrations in patients with HFrEF enrolled in GALACTIC-HF trial.
Methods: GALACTIC-HF was a randomized, double-blind, multicentre, event-driven trial that investigated the efficacy and safety of omecamtiv mecarbil compared to placebo in HF patients with LVEF ≤35%.
Danicamtiv reduces myosin's working stroke but activates the thin filament by accelerating actomyosin attachment.
Proc Natl Acad Sci U S A
August 2025
Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO 63110.
Heart failure is a leading cause of death worldwide, and even with current treatments, the 5-y transplant-free survival rate is only ~50 to 70%. As such, there is a need to develop new treatments for patients that improve survival and quality of life. Recently, there have been efforts to develop small molecules for heart failure that directly target components of the sarcomere, including cardiac myosin.
View Article and Find Full Text PDFInsights from electromechanical simulations to assess omecamtiv mecarbil efficacy in heart failure.
J Physiol
August 2025
Centro de Investigación e Innovación en Bioingeniería, Universitat Politècnica de València, Valencia, Spain.
Heart failure is a cardiac pathology characterized by causing myocardial dysfunction. The need to improve current pharmacotherapy for patients with heart failure has encouraged the development of more promising compounds. Currently, the amount of experimentation required during the early phases of drug development to assess safety and efficacy is costly, but computer simulations can help accelerate the process.
View Article and Find Full Text PDFLack of Effect of Omecamtiv Mecarbil on Smooth Muscle Myosin Phosphatase Target Subunit-1 (MYPT1) Phosphorylation and Hemodynamics in Rats.
Cureus
July 2025
Department of Anesthesiology, Seirei Mikatahara General Hospital, Hamamatsu, JPN.
Background It remains unclear whether omecamtiv mecarbil, a cardiac myosin direct activator, enhances vascular smooth muscle myosin function at clinical and supra-clinical doses. Aims The current study evaluated the effect of omecamtiv mecarbil, a cardiac myosin activator, on vascular smooth muscle contraction mediated by myosin phosphatase target subunit-1 (MYPT1) phosphorylation in rats. Methods Endothelium-denuded rat aortic rings underwent isometric force recordings (n = 7-9) and western immunoblotting (n = 5) to assess vascular smooth muscle MYPT1 phosphorylation.
View Article and Find Full Text PDF